Purpose of Technology: Sugammadex (SUG) is indicated for the reversal of neuromuscular blockade (NMB) induced by rocuronium bromide and vecuronium bromide during surgery. SUG selectively binds to neuromuscular blocking agents, thereby preventing further attachment of the NMB agents to acetylcholine receptors and facilitating the return of muscle function. SUG may provide complete reversal of NMB regardless of the level of blockade.
Controversy: The comparative effectiveness and safety of SUG relative to NEO has not yet been established, and questions remain regarding whether use of SUG results in improvements in quality-of-life (QOL) and functional outcomes. In addition, the potential benefits of SUG may not be sufficient to offset its high cost.
How does SUG compare with NEO with regard to reversal of NMB following surgery?
How does SUG compare with NEO with regard to safety for patients following surgery?
How does SUG compare with NEO with regard to functional and QOL outcomes?
Have definitive patient selection criteria been established for SUG?
If you have a Hayes login, click here to view the full report on the Knowledge Center.